The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Revealing Atropisomer Axial Chirality in Drug Discovery
Abstract
An often overlooked source of chirality is atropisomerism, which results from slow rotation along a bond axis due to steric hindrance and/or electronic factors. If undetected or not managed properly, this time‐dependent chirality has the potential to lead to serious consequences, because atropisomers can be present as distinct enantiomers or diastereoisomers with their attendant different properties. Herein we introduce a strategy to reveal and classify compounds that have atropisomeric chirality. Energy barriers to axial rotation were calculated using quantum mechanics, from which predicted high barriers could be experimentally validated. A calculated rotational energy barrier of 20 kcal mol−1 was established as a suitable threshold to distinguish between atropisomers and non‐atropisomers with a prediction accuracy of 86 %. This methodology was applied to subsets of drug databases in the course of which atropisomeric drugs were identified. In addition, some drugs were exposed that were not yet known to have this chiral attribute. The most valuable utility of this tool will be to predict atropisomerism along the drug discovery pathway. When used in concert with our compound classification scheme, decisions can be made during early discovery stages such as “hit‐to‐lead” and “lead optimization,” to foresee and validate the presence of atropisomers and to exercise options of removing, further stabilizing, or rendering the chiral axis of interest more freely rotatable via SAR design, thereby decreasing this potential liability within a compound series. The strategy can also improve drug development plans, such as determining whether a drug or series should be developed as a racemic mixture or as an isolated single compound. Moreover, the work described herein can be extended to other chemical fields that require the assessment of potential chiral axes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Challenge of Atropisomerism in Drug Discovery
Clayden, J., Moran, W. J., Edwards, P. J., & LaPlante, S. R. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901719 · Cited by 783
Self-citationPutting chirality to work: the strategy of chiral switches
Agranat, I., Caner, H., & Caldwell, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd915 · Cited by 637
Dynamic Kinetic Resolution of Biaryl Atropisomers via Peptide-Catalyzed Asymmetric Bromination
Gustafson, J. L., Lim, D., & Miller, S. J. (2010) · Science · doi:10.1126/science.1188403 · Cited by 461
Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A., Gold, R., Havrdova, E., Komoly, S., Selmaj, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60918-6 · Cited by 278
Eriksson, T., Bjöurkman, S., Roth, B., Fyge, Å., & Höuglund, P. (1995) · Chirality · doi:10.1002/chir.530070109 · Cited by 251
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
Polman, C., Barkhof, F., Sandberg-Wollheim, M., Linde, A., Nordle, O., & Nederman, T. (2005) · Neurology · doi:10.1212/01.wnl.0000154520.48391.69 · Cited by 227
Toxicity and Teratogenicity of Optical Isomers of Thalidomide
FABRO, S., SMITH, R. L., & WILLIAMS, R. T. (1967) · Nature · doi:10.1038/215296a0 · Cited by 200
Atropisomerie als Herausforderung in der Medikamentenentwicklung
Clayden, J., Moran, W. J., Edwards, P. J., & LaPlante, S. R. (2009) · Angewandte Chemie · doi:10.1002/ange.200901719 · Cited by 185
Self-citationJamshidi, A., Hunter, S., Hazrati, S., & Harrad, S. J. (2007) · Environmental Science & Technology · doi:10.1021/es062218c · Cited by 146
Reist, M., Carrupt, P., Francotte, E. R., & Testa, B. (1998) · Chemical Research in Toxicology · doi:10.1021/tx9801817 · Cited by 145
Cited by
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
Self-citationJohnson, T. W., Richardson, P. F., Bailey, S., Brooun, A., Burke, B. J., Collins, M. R., Cui, J. J., Deal, J. G., Deng, Y.-L., Dinh, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500261q · Cited by 594
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Atropisomerism in the Pharmaceutically Relevant Realm
Basilaia, M., Chen, M. H., Secka, J., & Gustafson, J. L. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00500 · Cited by 326
Lorthiois, E., Gerspacher, M., Beyer, K. S., Vaupel, A., Leblanc, C., Stringer, R., Weiss, A., Wilcken, R., Guthy, D. A., Lingel, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01438 · Cited by 110
Metadata
- Authors
- LaPlante, S. R., Edwards, P. J., Fader, L. D., Jakalian, A., & Hucke, O.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2011-01-05
- Volume
- 6
- Issue
- 3
- Pages
- 505-513
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2058616449
- Cited by
- 535
- References
- 18
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.